Infect Chemother.  2010 Feb;42(1):39-42. 10.3947/ic.2010.42.1.39.

An Alternative Approach to Tuberculosis Management with Intravenous Streptomycin

• Kim SY
• Hong HC
• Kim JH
• Ryu JW
• Choi HS
• Chung YT
• Joh JS

• KMID: 2170279
• DOI: http://doi.org/10.3947/ic.2010.42.1.39

Abstract

Streptomycin is currently utilized to treat advanced tuberculosis in Korea. However, the usefulness of intravascular streptomycin is not fully understood. In this study, streptomycin was administered intravenously in 30 patients. Intravenous administration of streptomycin may be a useful route of administration without undesirable toxicities.

Keyword

Intravenous streptomycin infusion; Mycobacterium tuberculosis

MeSH Terms

Administration, Intravenous
Humans
Korea
Mycobacterium tuberculosis
Streptomycin
Tuberculosis
Streptomycin

Reference

1. Hong YP, Kim SJ, Lew WJ, Lee EK, Han YC. The seventh nationwide tuberculosis prevalence survey in Korea, 1995. Int J Tuberc Lung Dis. 1998. 2:27–36.

2. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis. 2007. 11:571–576.

3. Centers for Disease Control and Prevention. Initial therapy for tuberculosis in the era of multidrug resistance. Recommendation of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep. 1993. 42(RR-7):1–8.

4. Driver AG, Worden JP Jr. Intravenous streptomycin. DICP. 1990. 24:826–828.

5. Ellner JJ, Hinman AR, Dooley SW, Fischl MA, Sepkowitz KA, Goldberger MJ, Shinnick TM, Iseman MD, Jacobs WR Jr. Tuberculosis symposium: emerging problems and promise. J Infect Dis. 1993. 168:537–551.

6. Choi SI, Bae JH, Kong SJ, Park JH. The actual condition of drug-resistant tuberculosis and treatment outcomes at a tuberculosis specialized hospital. Korean J Med. 2006. 70:172–182.

7. Peloquin CA, Berning SE. Comment: intravenous streptomycin. Ann Pharmacother. 1993. 27:1546–1547.

8. Zintel HA, Flippin HF, Nichols AC, Wiley MM, Rhoads JE. Studies on streptomycin in man, absorption, distribution, excretion and toxicity. Am J Med Sci. 1945. 210:421–430.

9. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br Med J. 1948. 2:769–782.

10. Anderson DG, Jewell M. The absorption, excretion, and toxicity of streptomycin in man. N Engl J Med. 1945. 233:485–491.

11. Heilman DH, Heilman FR, Hinshaw HC, Nichols DR, Herrell WE. Streptomycin; absorption, diffusion, excretion and toxicity. Am J Med Sci. 1945. 210:576–584.

12. Herrell WE. Waksman S, editor. Methods of administration and dosage. Streptomycin : nature and practical application. 1949. Baltimore: Williams & Wilkins Co.

13. Joint Streptomycin Committee for Tuberculosis. The effects of streptomycin on tuberculosis in man. JAMA. 1947. 135:634–641.

14. Zhu M, Burman WJ, Jaresko GS, Berning SE, Jelliffe RW, Peloquin CA. Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. Pharmacotherapy. 2001. 21:1037–1045.

15. Bass JB Jr, Farer LS, Hopewell PC, O'Brien R, Jacobs RF, Ruben F, Snider DE Jr, Thornton G. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med. 1994. 149:1359–1374.